

Zur Arzneimittelsicherheit von NSAR und COX-2-Hemmern

Thomas Herdegen, Kiel, und Joachim Fauler, Dresden

Literatur

- Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclooxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. *BMJ* 2005;330:1366.
- Singh G, Mithal A, Triadafilopoulos G. Both selective cox-2 inhibitors and non selective NSAIDs increase the risk of acute myocardial infarction in patients with arthritis: selectivity is with the patient, not the drug class. *Annals Rheum Dis* 2005;64(Suppl III):85.
- Singh G, Rosen Ramey D. NSAID induced gastrointestinal complications: the ARAMIS perspective – 1997. Arthritis, rheumatism, and aging medical information system. *J Rheumatol Suppl* 1998;51:8–16.
- Blower AL, Brooks A, Fenn GC, et al. Emergency admissions for upper gastrointestinal disease and their relation to NSAID use. *Aliment Pharmacol Ther* 1997;11:283–91.
- Hunt RH, Harper S, Watson DJ, et al. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events. *Am J Gastroenterol* 2003;98:1725–33.
- Lisse JR, Perlman M, Johansson G, et al. Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial. *Ann Intern Med* 2003;139:539–46.
- Martina S, Vesta K, Ripley T. Etoricoxib: A highly selective COX-2 inhibitor. *Ann Pharmacother* 2005;39:854–62.
- Ramey DR, Watson DJ, Yu C, et al. The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis. *Curr Med Res Opin* 2005;21:715–22.
- Schnitzer TJ, Burmester GR, Mysler E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. *Lancet* 2004;364:665–74.
- Singh G, Lanes S, Triadafilopoulos G. Risk of serious upper gastrointestinal and cardiovascular thromboembolic complications with meloxicam. *Am J Med* 2004;117:100–6.
- Müller P, Simon B. Kurzezeitige Schmerzmittel – Risiko für Magen und Darm. <http://kassenarzt.dgmedien-ar.de> 2005.
- Freestone S, Bello A. Comparison of the effects of celecoxib, meloxicam, and nimesulide on platelet function in healthy subjects. *Ann Rheum Dis* 2005;64(Suppl III):495.
- Schrör K. Cardiovascular risks of selective COX-2-inhibitors. *Dtsch Med Wochenschr* 2004;129:2653–6.
- Hegi TR, Bombeli T, Seifert B, et al. Effect of rofecoxib on platelet aggregation and blood loss in gynaecological and breast surgery compared with diclofenac. *Br J Anaesth* 2004;92:523–31.
- Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. *N Engl J Med* 2001;345:1809–17.
- Capone ML, Sciulli MG, Tacconelli S, et al. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. *J Am Coll Cardiol* 2005;45:1295–1301.
- Brune K, Hinz B. Selective cyclooxygenase-2 inhibitors: similarities and differences. *Scand J Rheumatol* 2004;33:1–6.
- Yaksh TL, Dirig DM, Conway CM, et al. The acute antihyperalgesic action of nonsteroidal, anti-inflammatory drugs and release of spinal prostaglandin E2 is mediated by the inhibition of constitutive spinal cyclooxygenase-2 (COX-2) but not COX-1. *J Neurosci* 2001;21:5847–53.
- Zeilhofer HU. The glycinergic control of spinal pain processing. *Cell Mol Life Sci* 2005;62:2027–35.
- Hunot S, Vila M, Teismann P, et al. JNK-mediated induction of cyclooxygenase-2 is required for neurodegeneration in a mouse model of Parkinson's disease. *Proc Natl Acad Sci U S A* 2004;101:665–70.
- Dahlen B, Szczeklik A, Murray JJ. Celecoxib in patients with asthma and aspirin intolerance. The Celecoxib in Aspirin-Intolerant Asthma Study Group. *N Engl J Med* 2001;344:142.
- El Miedany YM, Youssef SS, Ahmed I, et al. The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cyclooxygenase-2 inhibitor, in inflammatory bowel disease. *Ann Rheum Dis* 2005;64(Suppl III):321.
- Stevenson DD, Simon RA. Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma. *J Allergy Clin Immunol* 2001;108:47–51.
- Stiefelhagen P. Glykoprotein-IIb/IIIa-Rezeptorantagonisten als Mono- oder Kombinationstherapie. *Arzneimitteltherapie* 2004;22:346–7.
- Brown JR, DuBois RN. COX-2: a molecular target for colorectal cancer prevention. *J Clin Oncol* 2005;23:2840–55.
- Hallak A, Alon-Baron L, Shamir R, et al. Rofecoxib reduces polyp recurrence in familial polyposis. *Dig Dis Sci* 2003;48:1998–2002.
- Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. *N Engl J Med* 2005;352:1092–1102.
- Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. *N Engl J Med* 2000;343:1520–8.
- Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. *N Engl J Med* 2005;352:1071–80.
- Ott E, Nussmeier NA, Duke PC, et al. Efficacy and safety of the cyclooxygenase-2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. *J Thorac Cardiovasc Surg* 2003;125:1481–92.
- Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. *N Engl J Med* 2005;352:1081–91.
- White WB, Strand V, Roberts R, et al. Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus non-steroidal anti-inflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis. *Am J Ther* 2004;11:244–50.
- Reines SA, Block GA, Morris JC, et al. Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. *Neurology* 2004;62:66–71.
- Brinker A, Goldkind L, Bonnel R, et al. Spontaneous reports of hypertension leading to hospitalisation in association with rofecoxib, celecoxib, nabumetone and oxaprozin. *Drugs Aging* 2004;21:479–84.

Prof. Dr. med. Thomas Herdegen, Institut für Pharmakologie, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Hospitalstraße 4, 24105 Kiel
Prof. Joachim Fauler, Institut für Klinische Pharmakologie, Technische Universität Dresden, Fiedlerstraße 27, 01307 Dresden

35. Farkouh ME, Kirshner H, Harrington RA, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. *Lancet* 2004;364:675–84.
36. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclooxygenase-2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. *Lancet* 2005;365:475–81.
37. Kimmel SE, Berlin JA, Reilly M, et al. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. *Ann Intern Med* 2005;142:157–64.
38. Sowers JR, White WB, Pitt B, et al. The effects of cyclooxygenase-2 inhibitors and non-steroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. *Arch Intern Med* 2005;165:161–8.
39. Wieckhorst A, Tiroke A, Lins M, et al. [Acute coronary syndrome after diclofenac induced coronary spasm]. *Z Kardiol* 2005;94:274–9.
40. Fischer LM, Schlienger RG, Matter CM, et al. Current use of non-steroidal anti-inflammatory drugs and the risk of acute myocardial infarction. *Pharmacotherapy* 2005;25:503–10.
41. Ray WA, Stein CM, Hall K, et al. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. *Lancet* 2002;359:118–23.
42. Kurth T, Glynn RJ, Walker AM, et al. Inhibition of clinical benefits of aspirin on first myocardial infarction by non-steroidal anti-inflammatory drugs. *Circulation* 2003;108:1191–5.
43. Juni P, Nartey L, Reichenbach S, et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. *Lancet* 2004;364:2021–9.
44. Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. *N Engl J Med* 2003;348:891–9.
45. Cheng HF, Harris RC. Renal effects of non-steroidal anti-inflammatory drugs and selective cyclooxygenase-2 inhibitors. *Curr Pharm Des* 2005;11:1795–1804.
46. Stichtenoth DO, Froelich JC. COX-2 and the kidneys. *Curr Pharm Des* 2000;6:737–53.
47. Cipollone F, Rocca B, Patrono C. Cyclooxygenase-2 expression and inhibition in atherothrombosis. *Arterioscler Thromb Vasc Biol* 2004;24:246–55.
48. Rabausch K, Bretschneider E, Sarbia M, et al. Regulation of thrombomodulin expression in human vascular smooth muscle cells by COX-2-derived prostaglandins. *Circ Res* 2005;96:e1–6.
49. Forman JP, Stampfer MJ, Curhan GC. Non-narcotic analgesic dose and risk of incident hypertension in US women. *Hypertension* 2005;46:500–7.
50. Castaneda-Hernández G, Lozano-Cuenca J, Granados-Soto V. Lumiracoxib, a selective cox-2 inhibitor, is also able to produce peripheral analgesia by activation of the nitric oxide-cyclic GMP-potassium channel pathway. *Ann Rheum Dis* 2005;64(Suppl III):132.
51. Walter MF, Jacob RF, Day CA, et al. Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs. *Atherosclerosis* 2004;177:235–43.
52. Alvarez-Soria MA, Largo R, Santillana J, et al. Longterm celecoxib treatment decreases cox-2-synthesis and macrophage infiltration in human osteoarthritic synovial membrane independently of PGE₂ inhibition. *Ann Rheum Dis* 2005;64(Suppl III):496.
53. Masterbergen SC, Jansen NWD, Bijlsma JWJ, et al. Direct effects of different commonly used NSAIDs on human osteoarthritic cartilage. *Ann Rheum Dis* 2005;64(Suppl III):148.